Nirsevimab, a monoclonal antibody, may cause more severe RSV infection and death in some infants due to a mechanism that enhances the virus’ ability to infect cells.
Superb article, very important information...sharing wherever I can.
In May 2020 I wrote the following substack which among other things discusses the known issue of ADE (antibody dependent enhancement) with many different vaccines, including RSV:
SARS-CoV-2 Coronavirus Vaccine: Concerns from a Vaccine Safety Advocate
This references the following fantastic article which discusses numerous instances where vaccines caused injury and death via this mechanism of ADE, and it specifically calls out the previous failed RSV vaccine. So it seems reasonable to expect that anyone looking to develop a new RSV vaccine would be on the lookout for this problem. It doesn't sound like they did that, but we shouldn't be surprised because they certainly did not exercise due caution when developing myriad Covid vaccines.
Avoiding pitfalls in the pursuit of a COVID-19 vaccine
As they race to devise a vaccine, researchers are trying to ensure that their candidates don’t spur a counterproductive, even dangerous, immune system reaction known as immune enhancement.
Researchers at the time were pursuing a vaccine against RSV, the leading cause of severe respiratory illness in infants. In trials of one vaccine candidate, several children who received the vaccine developed a serious illness when infected with the natural virus (7). Two toddlers died. In this case, researchers noticed severe damage and the unexpected presence of lots of neutrophils and eosinophils, both immune cells, in the children's lung tissue. A similar inflammatory response was seen in animal models of RSV, in which cytokines, a type of immune cell, had invaded and damaged tissue.
“That really killed RSV vaccines for a generation,” says Peter Hotez, a vaccine researcher and dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, TX. After more than 50 years of further study, a candidate RSV vaccine is finally back in clinical trials.
Superb article, very important information...sharing wherever I can.
In May 2020 I wrote the following substack which among other things discusses the known issue of ADE (antibody dependent enhancement) with many different vaccines, including RSV:
SARS-CoV-2 Coronavirus Vaccine: Concerns from a Vaccine Safety Advocate
https://dfoster.substack.com/p/sars-cov-2-coronavirus-vaccine-concerns
This references the following fantastic article which discusses numerous instances where vaccines caused injury and death via this mechanism of ADE, and it specifically calls out the previous failed RSV vaccine. So it seems reasonable to expect that anyone looking to develop a new RSV vaccine would be on the lookout for this problem. It doesn't sound like they did that, but we shouldn't be surprised because they certainly did not exercise due caution when developing myriad Covid vaccines.
Avoiding pitfalls in the pursuit of a COVID-19 vaccine
As they race to devise a vaccine, researchers are trying to ensure that their candidates don’t spur a counterproductive, even dangerous, immune system reaction known as immune enhancement.
https://www.pnas.org/doi/10.1073/pnas.2005456117
Researchers at the time were pursuing a vaccine against RSV, the leading cause of severe respiratory illness in infants. In trials of one vaccine candidate, several children who received the vaccine developed a serious illness when infected with the natural virus (7). Two toddlers died. In this case, researchers noticed severe damage and the unexpected presence of lots of neutrophils and eosinophils, both immune cells, in the children's lung tissue. A similar inflammatory response was seen in animal models of RSV, in which cytokines, a type of immune cell, had invaded and damaged tissue.
“That really killed RSV vaccines for a generation,” says Peter Hotez, a vaccine researcher and dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston, TX. After more than 50 years of further study, a candidate RSV vaccine is finally back in clinical trials.
Delete, abolish, forbid, erase pharma